FUJIFILM Diosynth Biotechnologies (FDB), is a leading CDMO with demonstrated leadership in the development and manufacture of recombinant biopharmaceuticals and gene therapies. These laboratories were realized through a JPY1 billion ($9M USD) investment which is part of the greater JPY14…, FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), has announced the successful completion of its 100th program using its pAVEway™ Advanced Protein Expression system which was introduced to the market during the BIO 2007 convention…, FUJIFILM Corporation (President: Kenji Sukeno) will increase production capacity by investing about JPY14 billion ($130m) in the USA and UK in order to expand the…, FUJIFILM Diosynth Biotechnologies, has announced the expansion of its Monoclonal Antibody development and manufacturing services with the introduction of its Saturn mAb Platform™. Further investments are planned at the company's other locations; details shall be announced in first quarter of 2019. At BIO 2018 FUJIFILM announces the opening of Cambridge Collaboration Center to expand its footprint, FUJIFILM ANNOUNCES THE OPENING OF ITS FLEXIBLE MANUFACTURING FACILITY FOR THE PRODUCTION OF CLINICAL AND COMMERCIAL GENE THERAPIES FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract…, FUJIFILM Corporation (President: Kenji Sukeno) today announced the on-time completion of Qualification activities, enabling commencement of cGMP operations for its Saturn™ mAb manufacturing facilities at FUJIFILM Diosynth Biotechnologies (“FDB”), a world leading cGMP Contract Development and Manufacturing Organization in College…, FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), is pleased to announce that Martin Meeson, President and COO of FUJIFILM Diosynth Biotechnologies U.S.A., is scheduled to present at EBD’s Biotech Showcase 2018 event during the…, FUJIFILM Diosynth Biotechnologies, a leading global Contract Development and Manufacturing Organization (CDMO), is pleased to announce that its Chief Executive Officer, Steve Bagshaw, has been awarded “North East Business Executive of the Year 2017”; a prestigious award organized by The…, FUJIFILM Corporation (President: Kenji Sukeno) is to invest a total of 3.2billion yen on its CDMO* sites in the U.S.A. and the U.K. in order to accelerate the expansion of the company’s business for developing and manufacturing biopharmaceuticals** under contract…, FUJIFILM Diosynth Biotechnologies has announced its opening of the 10,000 square foot, state-of-the-art cell culture Process Development Laboratories in Wilton Centre, Teesside. Companies in this industry manufacture and process pharmaceutical products. Detailed profiles of all businesses owned and operated by this company for insights and prospecting. “We provide high-quality products and services through leading-edge, proprietary technologies in various fields,” said Takatoshi Ishikawa, Director, Senior Vice President, General Manager of Bio CDMO Division, FUJIFILM Corporation. Ces médicaments prometteurs seront ainsi produits sur le site danois de Fujifilm Diosynth Biotechnologies, dès avril 2021. Fujifilm Diosynth Biotechnologies U.S.A., Inc. has 432 total employees across all of its locations and generates $152.61 million in sales (USD). Biopharmaceutical production requires the use of advanced manufacturing technologies and facilities for culturing, separation and purification. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Fujifilm Diosynth Biotechnologies U.S.A., Inc. is located in Morrisville, NC, United States and is part of the Pharmaceutical Manufacturing Industry. *Contacts and Principals counts are estimates and may differ from the actual number of contacts available in D&B Hoovers. Continuously updated. High quality data. Biopharmaceuticals are gaining an increasing share of the overall pharmaceuticals market due to the potential of therapies to produce strong results with less side-effects. See our. FUJIFILM Diosynth Biotechnologies (FDB) iPSCells Cellular Dynamics International (CDI) Somatic Stem Cells Japan Tissue Engineering (J-TEC) • Enhanced production facilities for the expansion of bio CDMO production capabilities • Made a leading company in the development and manufacturing of Extensive viral vector experience, including the process development, scale up and cGMP production of: Adenovirus, Adeno-associated virus (AAV), Lentivirus, Poxvirus and Baculovirus among others. For over 25 years our focus has been on supporting our customers with the development and manufacture of recombinant proteins, viral vaccines and gene therapies. FUJIFILM Diosynth Biotechnologies today announced that it will manufacture Eli Lilly and Company’s COVID-19 therapeutic antibody at its GMP facility in Hillerød, Denmark, deploying capacity reserved for the COVID-19 Therapeutics Accelerator. Fujifilm's investment in the United Kingdom site will allow FDB to respond to the increased demand of microbial expressed therapies. FUJIFILM Diosynth Biotechnologies (FDB), a leading global biologics and gene therapy Contract Development and Manufacturing Organization (CDMO) has announced its participation as a founding member in a newly announced center for innovation and manufacturing of next-generation medicines. Learn about Investor Relations. -Doubling the drug substance production capacity -Establishing end-to-end capabilities in one site, including drug substance manufacturing, fill/finish, assembly, labeling and packaging, HILLERØD, Denmark, April 30, 2020 – FUJIFILM Diosynth Biotechnologies, a world leading biologics-Contract Development and Manufacturing Organization (CDMO), today announced that it will reserve manufacturing…, Capabilities expand to supplying plasmids for triple transfections. Fujifilm is helping make the world a better, healthier, and more interesting place. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. The expansion will be made in its United Kingdom site and is scheduled to be operational after 2022. Learn more about what we’re about. All product and company names herein may be trademarks of their registered owners. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For the year ended March 31, 2019, the company had global revenues of $22 billion, at an exchange rate of 111 yen to the dollar. 読む Financial Results (consolidated) for the Second Quarter ended September 30, 2020. These services will…, FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies,…, FUJIFILM Corporation (President: Kenji Sukeno) announced plans to invest approximately JPY 10 billion (approximately $90 million U.S. dollars) in order to expand its Bio Contract…, FUJIFILM Diosynth Biotechnologies Announces Co-Chair Role Of Its CEO, Steve Bagshaw, In The Preparation Of The United Kingdom’s Bioeconomy Growth Strategy, FUJIFILM announces that AMECRYS Collaboration reaches project milestone to develop new technologies to improve Downstream Processing of Monoclonal Antibodies. For more information, please visit: www.fujifilmholdings.com. Capacity increase will support production of high throughput and large volume gene therapy products. Fujifilm is investing in FDB's facilities to increase production capacity to meet its growing customer demands. © Dun & Bradstreet, Inc. 2000 - 2020. This new round of investments will include the addition of 2000L single use cell culture manufacturing trains, cell culture purification suites and new microbial recovery suites to its existing facilities in North Carolina. FUJIFILM Corporation, Tokyo, Japan is one of the major operating companies of FUJIFILM Holdings Corporation. Diosynth, or Fujifilm Diosynth Biotechnologies (FDB), is a company that develops and offers manufacturing processes for active ingredients for pharmaceutical companies.. History.